Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022) Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022) Publication ID: SMRC0416010 Publication May 2, 2016 Date: Pages: 141 Publisher: Stratistics MRC Countries: Global [1] $4,150.00 Publication Type * - Select - Please choose the suitable license type from above. More details are at given under tab "Report License Types" below. Add to cart Treatments [2] Healthcare [3]
Pharma & Healthcare [4] Description: According to Stratistics MRC, the Global Diabetic Retinopathy Treatment market is expected to reach $10.24 billion by 2022. Rising prevalence of diabetics, increasing management financial support, change in lifestyle and global aging population are the factors driving the market growth. However, Lack of accurate diagnosis, a lack of skilled ophthalmologist coupled with poor infrastructure and extended approval time for drugs are hampering the growth of global diabetic retinopathy market. Increase in awareness of diabetic retinopathy treatment and improvement of patient monitoring are some of the major trends in the market. The two main stages of diabetic retinopathy are non-proliferated and proliferated. Proliferated diabetic retinopathy is the mainly insecure stage and has the risk of detachment into the vitreous leading to severe vision loss. North America leads the global diabetic retinopathy market due to vast number of aging population. The Asia Pacific diabetic retinopathy market is expected to witness profitable growth over the estimated period due to the occurrence of unmet needs in the developing countries such as China and India. These countries are expected to be the fastest growing diabetic retinopathy markets in Asia-Pacific region. Some of the key players in the market include Regeneron Pharmaceuticals Inc., ThromboGenics, Genentech, Bayer Healthcare, Alimera Sciences, Actavis PLC, BCN Peptides, Novartis AG, Ampio Pharmaceuticals, Kowa Group, Sirnaomics Incorporation, Abbott Laboratories Ltd, Glycadia Pharmaceuticals, Alcon Laboratories Inc. and Parexel International Corp. Type of Treatments Covered: Intraocular Steroid Injection Vitrectomy Anti-Vascular Endothelial Growth Factor (VEGF) drug Laser Surgery Disease Type Covered: Proliferative Diabetic Retinopathy (PDR) Non-Proliferative Diabetic Retinopathy (NPDR) o Moderate o Mild o Severe End Users Covered: Ophthalmic Clinics Ambulatory Surgical Centers Hospitals Other End Users
Regions Covered: North America o US o Canada o Mexico Europe o Germany o France o Italy o UK o Spain o Rest of Europe Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements Table Of Contents:
1 Executive Summary 2 Preface 2.1 Abstract 2.2 Stake Holders 2.3 Research Scope 2.4 Research Methodology 2.4.1 Data Mining 2.4.2 Data Analysis 2.4.3 Data Validation 2.4.4 Research Approach 2.5 Research Sources 2.5.1 Primary Research Sources 2.5.2 Secondary Research Sources 2.5.3 Assumptions 3 Market Trend Analysis 3.1 Introduction 3.2 Drivers 3.3 Restraints 3.4 Opportunities 3.5 Threats 3.6 End User Analysis 3.7 Emerging Markets 4 Porters Five Force Analysis 4.1 Bargaining power of suppliers 4.2 Bargaining power of buyers 4.3 Threat of substitutes 4.4 Threat of new entrants 4.5 Competitive rivalry 5 Global Diabetic Retinopathy Treatment Market, By Treatment type 5.1 Introduction 5.2 Intraocular Steroid Injection 5.3 Vitrectomy 5.4 Anti-Vascular Endothelial Growth Factor (VEGF) drug 5.5 Laser Surgery 6 Global Diabetic Retinopathy Treatment Market, By Disease Type 6.1 Introduction
6.2 Proliferative Diabetic Retinopathy (PDR) 6.3 Non-Proliferative Diabetic Retinopathy (NPDR) 6.3.1 Moderate 6.3.2 Mild 6.3.3 Severe 7 Global Diabetic Retinopathy Treatment Market, By End User 7.1 Introduction 7.2 Ophthalmic Clinics 7.3 Ambulatory Surgical Centers 7.4 Hospitals 7.5 Other End Users 8 Global Diabetic Retinopathy Treatment Market, By Geography 8.1 North America 8.1.1 US 8.1.2 Canada 8.1.3 Mexico 8.2 Europe 8.2.1 Germany 8.2.2 France 8.2.3 Italy 8.2.4 UK 8.2.5 Spain 8.2.6 Rest of Europe 8.3 Asia Pacific 8.3.1 Japan 8.3.2 China 8.3.3 India 8.3.4 Australia 8.3.5 New Zealand 8.3.6 Rest of Asia Pacific 8.4 Rest of the World 8.4.1 Middle East 8.4.2 Brazil 8.4.3 Argentina 8.4.4 South Africa 8.4.5 Egypt 9 Key Developments 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers 9.3 New Product Launch 9.4 Expansions 9.5 Other Key Strategies 10 Company Profiling 10.1 Regeneron Pharmaceuticals Inc. 10.2 ThromboGenics 10.3 Genentech 10.4 Bayer Healthcare 10.5 Alimera Sciences 10.6 Actavis PLC 10.7 BCN Peptides 10.8 Novartis AG 10.9 Ampio Pharmaceuticals 10.10 Kowa Group 10.11 Sirnaomics Incorporation 10.12 Abbott Laboratories Ltd 10.13 Glycadia Pharmaceuticals 10.14 Alcon Laboratories Inc. 10.15 Parexel International Corp. List of Tables 1 Global Diabetic Retinopathy Treatment Market Outlook, By Region (2013-2022) 2 Global Diabetic Retinopathy Treatment Market Outlook, By Treatment type (2013-2022) 3 Global Diabetic Retinopathy Treatment Market Outlook, By Intraocular Steroid Injection (2013-2022) 4 Global Diabetic Retinopathy Treatment Market Outlook, By Vitrectomy (2013-2022) 5 Global Diabetic Retinopathy Treatment Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) drug (2013-2022) 6 Global Diabetic Retinopathy Treatment Market Outlook, By Laser Surgery (2013-2022) 7 Global Diabetic Retinopathy Treatment Market Outlook, By Disease Type (2013-2022) 8 Global Diabetic Retinopathy Treatment Market Outlook, By Proliferative Diabetic Retinopathy (PDR) (2013-2022) 9 Global Diabetic Retinopathy Treatment Market Outlook, By Non-Proliferative Diabetic Retinopathy (NPDR) (2013-2022) 10 Global Diabetic Retinopathy Treatment Market Outlook, By Moderate (2013-2022) 11 Global Diabetic Retinopathy Treatment Market Outlook, By Mild (2013-2022) 12 Global Diabetic Retinopathy Treatment Market Outlook, By Severe (2013-2022) 13 Global Diabetic Retinopathy Treatment Market Outlook, By End User (2013-2022) 14 Global Diabetic Retinopathy Treatment Market Outlook, By Ophthalmic Clinics (2013-2022)
15 Global Diabetic Retinopathy Treatment Market Outlook, By Ambulatory Surgical Centers (2013-2022) 16 Global Diabetic Retinopathy Treatment Market Outlook, By Hospitals (2013-2022) 17 Global Diabetic Retinopathy Treatment Market Outlook, By Other End Users (2013-2022) 18 North America Diabetic Retinopathy Treatment Market Outlook, By Treatment type (2013-2022) 19 North America Diabetic Retinopathy Treatment Market Outlook, By Intraocular Steroid Injection (2013-2022) 20 North America Diabetic Retinopathy Treatment Market Outlook, By Vitrectomy (2013-2022) 21 North America Diabetic Retinopathy Treatment Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) drug (2013-2022) 22 North America Diabetic Retinopathy Treatment Market Outlook, By Laser Surgery (2013-2022) 23 North America Diabetic Retinopathy Treatment Market Outlook, By Disease Type (2013-2022) 24 North America Diabetic Retinopathy Treatment Market Outlook, By Proliferative Diabetic Retinopathy (PDR) (2013-2022) 25 North America Diabetic Retinopathy Treatment Market Outlook, By Non-Proliferative Diabetic Retinopathy (NPDR) (2013-2022) 26 North America Diabetic Retinopathy Treatment Market Outlook, By Moderate (2013-2022) 27 North America Diabetic Retinopathy Treatment Market Outlook, By Mild (2013-2022) 28 North America Diabetic Retinopathy Treatment Market Outlook, By Severe (2013-2022) 29 North America Diabetic Retinopathy Treatment Market Outlook, By End User (2013-2022) 30 North America Diabetic Retinopathy Treatment Market Outlook, By Ophthalmic Clinics (2013-2022) 31 North America Diabetic Retinopathy Treatment Market Outlook, By Ambulatory Surgical Centers (2013-2022) 32 North America Diabetic Retinopathy Treatment Market Outlook, By Hospitals (2013-2022) 33 North America Diabetic Retinopathy Treatment Market Outlook, By Other End Users (2013-2022) 34 Europe Diabetic Retinopathy Treatment Market Outlook, By Treatment type (2013-2022) 35 Europe Diabetic Retinopathy Treatment Market Outlook, By Intraocular Steroid Injection (2013-2022) 36 Europe Diabetic Retinopathy Treatment Market Outlook, By Vitrectomy (2013-2022) 37 Europe Diabetic Retinopathy Treatment Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) drug (2013-2022) 38 Europe Diabetic Retinopathy Treatment Market Outlook, By Laser Surgery (2013-2022) 39 Europe Diabetic Retinopathy Treatment Market Outlook, By Disease Type (2013-2022)
40 Europe Diabetic Retinopathy Treatment Market Outlook, By Proliferative Diabetic Retinopathy (PDR) (2013-2022) 41 Europe Diabetic Retinopathy Treatment Market Outlook, By Non-Proliferative Diabetic Retinopathy (NPDR) (2013-2022) 42 Europe Diabetic Retinopathy Treatment Market Outlook, By Moderate (2013-2022) 43 Europe Diabetic Retinopathy Treatment Market Outlook, By Mild (2013-2022) 44 Europe Diabetic Retinopathy Treatment Market Outlook, By Severe (2013-2022) 45 Europe Diabetic Retinopathy Treatment Market Outlook, By End User (2013-2022) 46 Europe Diabetic Retinopathy Treatment Market Outlook, By Ophthalmic Clinics (2013-2022) 47 Europe Diabetic Retinopathy Treatment Market Outlook, By Ambulatory Surgical Centers (2013-2022) 48 Europe Diabetic Retinopathy Treatment Market Outlook, By Hospitals (2013-2022) 49 Europe Diabetic Retinopathy Treatment Market Outlook, By Other End Users (2013-2022) 50 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Treatment type (2013-2022) 51 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Intraocular Steroid Injection (2013-2022) 52 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Vitrectomy (2013-2022) 53 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) drug (2013-2022) 54 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Laser Surgery (2013-2022) 55 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Disease Type (2013-2022) 56 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Proliferative Diabetic Retinopathy (PDR) (2013-2022) 57 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Non-Proliferative Diabetic Retinopathy (NPDR) (2013-2022) 58 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Moderate (2013-2022) 59 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Mild (2013-2022) 60 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Severe (2013-2022) 61 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By End User (2013-2022) 62 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Ophthalmic Clinics (2013-2022) 63 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Ambulatory Surgical Centers (2013-2022) 64 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Hospitals (2013-2022) 65 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Other End Users (2013-2022)
66 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Treatment type (2013-2022) 67 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Intraocular Steroid Injection (2013-2022) 68 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Vitrectomy (2013-2022) 69 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) drug (2013-2022) 70 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Laser Surgery (2013-2022) 71 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Disease Type (2013-2022) 72 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Proliferative Diabetic Retinopathy (PDR) (2013-2022) 73 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Non-Proliferative Diabetic Retinopathy (NPDR) (2013-2022) 74 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Moderate (2013-2022) 75 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Mild (2013-2022) 76 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Severe (2013-2022) 77 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By End User (2013-2022) 78 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Ophthalmic Clinics (2013-2022) 79 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Ambulatory Surgical Centers (2013-2022) 80 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Hospitals (2013-2022) 81 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Other End Users (2013-2022) Companies Mentioned: NA License Types: Single User License (PDF) This license allows for use of a publication by one person. This person may print out a single copy of the publication. This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons. Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Site License (PDF)* This license allows for use of a publication by all users within one corporate location, e.g. a regional office. These users may print out a single copy of the publication. These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased. Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Global License (PDF)* This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company. Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization. These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. *If Applicable. Source URL: https://www.marketresearchreports.com/stratistics-mrc/diabetic-retinopathy-treatment-glbal-market-outlook-2015-2022 Links [1] https://www.marketresearchreports.com/countries/global [2] https://www.marketresearchreports.com/treatments
[3] https://www.marketresearchreports.com/healthcare [4] https://www.marketresearchreports.com/pharma-healthcare